Cadrenal Therapeutics Reports Increased Net Loss and Operating Expenses for First Half of 2025

Cadrenal Therapeutics, Inc. reported a net loss of $7.5 million for the six months ended June 30, 2025, compared to a net loss of $4.1 million for the same period in 2024, marking an increase of approximately 85%. The company's total operating expenses for the first half of 2025 reached $7.7 million, up from $4.2 million in the prior year, driven primarily by a significant rise in general and administrative expenses, which increased by 110% to $4.9 million. This surge was attributed to higher costs associated with being a public company, increased stock-based compensation, and personnel-related expenses.

In terms of financial position, Cadrenal's total assets decreased to $5.98 million as of June 30, 2025, down from $10.12 million at the end of 2024. The decline in cash and cash equivalents was notable, dropping to $5.57 million from $10.02 million. The company’s accumulated deficit also widened to $33.2 million, reflecting ongoing operational losses. Current liabilities decreased significantly to $1.68 million from $2.68 million, indicating improved management of short-term obligations.

Operationally, Cadrenal is focused on advancing its lead drug candidate, tecarfarin, which is designed to address unmet needs in anticoagulation therapy for patients with specific cardiovascular conditions. The company has received orphan drug and fast-track designations from the FDA for tecarfarin, which is currently in late-stage development. The company announced plans to initiate clinical trials for tecarfarin in patients with end-stage kidney disease transitioning to dialysis, with enrollment expected to begin later this year.

During the six months ended June 30, 2025, Cadrenal raised approximately $3.2 million through its at-the-market facility, selling 186,294 shares of common stock at an average price of $17.97 per share. The company also reported a decrease in research and development expenses, which totaled $2.7 million for the first half of 2025, up from $1.9 million in the previous year. This increase was primarily due to higher costs associated with chemistry, manufacturing, and controls, as well as clinical trial preparations.

Looking ahead, Cadrenal anticipates that its current cash reserves will be sufficient to fund operations for at least the next twelve months. However, the company will require additional funding to conduct further clinical trials, including a Phase 3 trial for tecarfarin. Management plans to explore various financing options, including partnerships and equity sales, to support its ongoing development efforts.